November 15, 2011 – Abbott announced positive long-term data from the two-stage ABSORB trial, which is evaluating the Absorb drug-eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease. Five-year results from the first stage and two-year and 18-month data from the second stage of the ABSORB trial were recently presented at the 2011 American Heart Association's Scientific Sessions in Orlando and the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in San Francisco.

November 15, 2011 – The new full iterative technology (FIT) now available on the BrightView XCT uses advanced algorithms for the truest picture possible. New clinical cases show that concurrent imaging allows for shorter exams and smarter assessments.  

November 15, 2011 — Data from the BRIDGE clinical trial demonstrate that intravenous use of the drug cangrelor was effective at maintaining platelet inhibition in patients on thienopyridines who required bypass surgery. Trial results were presented at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

November 15, 2011 — A randomized clinical trial examining angioplasty approaches in patients with ST elevation acute coronary syndrome (STEACS) suggests the transradial approach should be the recommended access route. The results of the trial found transradial access preferable to the femoral approach.

November 15, 2011 — A new clinical trial is testing the efficacy of rotational atherectomy (or rotablation, a process of drilling through plaque deposits) prior to implantation of a drug-eluting stent (DES). The trial found the process was not superior to standard balloon angioplasty and decreased the efficacy of the stent in reducing new tissue growth within the blood vessel.